AbbVie filed suit in D.C. asking judges to narrow who qualifies for 340B discounts, challenging HRSA guidance and raising stakes for hospitals.

Joe and Rika Mansueto pledged $50 million to UChicago to launch a challenge recruiting 20 AI‑focused scholars across disciplines.

A Napa nonprofit's internship pipeline helped build a prototype Virtual Neurologist AR headset that organizers say could speed stroke diagnosis and is heading toward ambulance pilots.

Lake Forest-based Assertio agreed to be bought for $18 a share (~$125.1M) and sold seven branded drugs to Cosette for $35M.

Helen and Jacob Shaham pledged $30 million to FIU Medicine, and the university will name its new on-campus academic medical center in their honor. The gift aims to expand scholarships, research and outpatient services at a facility slated for 2028.

Wasabi has closed its acquisition of Seagate’s Lyve Cloud, folding the S3‑compatible platform into its hot‑cloud stack and accelerating its push into AI‑ready storage.

Ampera opened a Palm Beach Gardens HQ and factory to build container‑sized, thorium microreactors it calls "ultra‑safe." The company promises jobs and is now pursuing NRC pre‑application.

Experts warned AI could bring big jobs and investment to Dallas‑Fort Worth while testing power, water and workforce capacity across the region.

Indiana University physicians were co‑authors on a NEJM trial showing enfortumab vedotin plus pembrolizumab produced large survival gains for certain bladder cancer patients. IU sites helped enroll and analyze the data behind the finding.

Researchers at the University of Miami are testing stem‑cell strategies to replace neurons lost in Parkinson’s disease; early lab and trial signals offer cautious hope.

Axiom Space is assembling the AxEMU lunar suits in Houston — seamstresses and engineers are running pools and vacuum tests as NASA moves toward Artemis surface operations.

Stanford Medicine has installed a compact Mevion proton system at its Palo Alto Cancer Center that hospital leaders say could begin treating patients this summer and reduce radiation to healthy tissue.

Life Biosciences closed an $80M Series D to fund a first-in-human ER-100 trial and expand its partial epigenetic reprogramming pipeline.